




ChemoCentryx, Inc.  
Investor Relations Department  
850 Maude Avenue  
Mountain View, CA 94043  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#) 

**NASDAQ: CCXI**

Last Trade:	7.44
Trade Time:	4:00 PM ET Oct 18, 2017
Change:	-0.13  (-1.717%)
Day Range	7.37 - 7.67
52-Week Range	5.52 - 10.80
Volume	88,068

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

ChemoCentryx is a biopharmaceutical company focused exclusively on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. Our drug candidates target specific chemokines or chemoattractant receptors, thereby blocking the inflammatory response driven by that particular chemokine while leaving the rest of the immune system unaffected. Our goal is to discover, develop and commercialize therapeutics with distinct advantages over currently marketed therapies in our disease areas of focus, thereby maximizing ... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- Sep 5, 2017  
[ChemoCentryx to Present at Three Upcoming Investor Conferences](#)
- Aug 8, 2017  
[ChemoCentryx Reports Second Quarter 2017 Financial Results and Recent Highlights](#)
- Jul 26, 2017  
[ChemoCentryx to Hold Second Quarter 2017 Financial Results Conference Call on Tuesday, August 8, 2017](#)
- Jun 6, 2017  
[Oral Presentations at ERA-EDTA Congress Highlight Fourth Potential Indication for Avacopan and Potential for CCR2 Inhibition in Focal Segmental Glomerulosclerosis \(FSGS\)](#)
- May 24, 2017  
[ChemoCentryx to Present at Two Upcoming Investor Conferences](#)

## Financials [\[ View all \]](#)

- Mar 14, 2017  
[Annual Report \(10-K\)](#)
- Apr 10, 2017  
[Proxy Statement \(DEF 14A\)](#)
- Aug 8, 2017  
[Quarterly Report \(10-Q\)](#)
- May 10, 2017  
[Quarterly Report \(10-Q\)](#)
- Nov 8, 2016  
[Quarterly Report \(10-Q\)](#)